Navigation Links
Essilor Cancels 1,600,000 Shares
Date:12/2/2008

CHARENTON-LE-PONT, France, December 3 /PRNewswire-FirstCall/ -- On November 28, Essilor cancelled 1,600,000 shares, in line with its commitment to shareholders to offset the dilutive impact of Oceane bond conversions and the Company's stock option plans.

These latest cancellations concerned shares acquired under the 6.9 million share buyback program authorized by the Board of Directors on July 15, 2008 to offset the dilutive impact of converting outstanding Oceane bonds due in 2010. To date, a total of 1.5 million shares have been bought back under this program.

At the same time, in line with its standard practice, Essilor has cancelled shares bought back on the market in order to offset the dilutive impact of its stock option plans, and also of its performance share plans which are covered by shares held in treasury stock.

Following these cancellations, Essilor's capital is represented by 210,445,678 shares.

Essilor International is the world leader in ophthalmic optical products, offering a wide range of lenses under the flagship Varilux(R), Crizal(R), Essilor(R) and Definity(R) brands to correct myopia, hyperopia, presbyopia and astigmatism. Essilor operates worldwide through 15 production sites, 270 lens finishing laboratories and local distribution networks. The Essilor share trades on the Euronext Paris market and is included in the CAC 40 index (ISIN: FR 0000121667; Reuters: ESSI.PA; Bloomberg: EF FP).

    Investor Relations and Financial Communications
    Phone: +33(0)1-49-77-42-16
   http://www.essilor.com

'/>"/>
SOURCE Essilor
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Essilors 2007 Third-Quarter Report
2. Essilor Cancels 700,000 Shares
3. Essilor: New Acquisitions in the United States and Brazil
4. Essilor : Nomination of Hubert Sagnieres
5. Essilors First-Half 2008 Results
6. Essilor Finalizes Satisloh Agreement
7. Jazz Pharmaceuticals Cancels Presentation Planned for November 19, 2008 at Lazard Capital Markets 5th Annual Healthcare Conference
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol APPY
10. Neuralstem Shares Accepted for Trading on Amex(R)
11. Bionovo Announces the Pricing of Public Offering of Shares of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Northwest Biotherapeutics (NASDAQ: NWBO ) ... personalized immune therapies for solid tumor cancers, announced today ... American Society Of Clinical Oncology (ASCO) meeting in ... in immune therapy.  (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ) ... pre-eminent conference focused on clinical treatment of cancer, with ...
(Date:5/23/2013)... 2013 Pusan National University Yangsan Hospital, ... and contract research company focused on research and ... today a publication reporting the induction of functional ... and immunotherapeutic vaccinia JX-594 (pexastimogene devacirepvec; Jennerex Inc.). ... the May 15 th , 2013 issue of ...
(Date:5/23/2013)... 2013 Watlow®, an industry leader ... systems, recently introduced its new catalog, Watlow® Heating ... in designing and manufacturing industrial heaters, Watlow provides ... serve diverse customer needs. , A description of ... beginning of the book. These options allow high ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 iLuv Creative ... of accessories for the mobile lifestyle, announces they are ... protect, and manage multiple iPad devices efficiently. Winner of ... the 2012 Good Design award, MultiCharger-X is revolutionizing the ... wherever it is deployed. , MultiCharger-X (iAD910) ...
Breaking Biology Technology:NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3Watlow Introduces Its New Industrial Heater Catalog 2iLuv Now Shipping the All New MultiCharger-X 2iLuv Now Shipping the All New MultiCharger-X 3
... , MONROVIA, Calif., June 11 STAAR Surgical Company ... and marketer of minimally invasive ophthalmic products, today announced ... Epiphany Injector System for use with the Affinity(TM) Collamer(R) ... of the Epiphany will usher in a new era ...
... COLLEGEVILLE, Pa., June 11 New data from ... that Wyeth,s (NYSE: WYE ) investigational pneumococcal vaccine, ... potential to provide coverage against the 13 most prevalent serotypes ... death in children younger than five worldwide. , ...
... HONG KONG, June 11 /PRNewswire-Asia/ -- With ... week, Filligent, the Australian-led biotech company,is mobilizing stocks of ... A (H1N1) across Australia. The BioMask is the first ... seconds of contact while retaining,the breathability required by front-line ...
Cached Biology Technology:STAAR Surgical Receives FDA Clearance for the Epiphany(TM) Injector System 2STAAR Surgical Receives FDA Clearance for the Epiphany(TM) Injector System 3New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 2New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 3New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 4New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 5New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 6Australia: Face Mask That Kills Swine Flu Readied for Australian Pandemic Fight 2Australia: Face Mask That Kills Swine Flu Readied for Australian Pandemic Fight 3Australia: Face Mask That Kills Swine Flu Readied for Australian Pandemic Fight 4
(Date:5/23/2013)... wrapping of genomic DNA around nucleosomes in the ... A team of Ludwig-Maximilians-Universitaet (LMU) in Munich now ... be locally displaced from nucleosomes for transcription. , ... in the cell nucleus, wrapped around disk-shaped particles ... four different histone proteins and accommodating two loops ...
(Date:5/23/2013)... WASHINGTON Given the implications for the overall ... should play a primary role in ensuring that ... least 60 minutes per day of vigorous or ... the Institute of Medicine. Recent estimates suggest ... this evidence-based guideline for promoting better health and ...
(Date:5/23/2013)... or harsh treatments because science fails to identify ... the disease. Researchers at Case Western Reserve University ... that allows patients to safely choose to do ... drastic measures. , The project is one of ... engineering at Case Western Reserve and director of ...
Breaking Biology News(10 mins):Biochemistry: Unspooling DNA from nucleosomal disks 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3
... In a paper available at the online site of ... of UCLA researchers reports for the first time that ... stimulating production of the antimicrobial protein cathelicidin. The ... active form of vitamin D, leading to production of ...
... basic molecules that make up all living things have ... people are right- or left-handed. This chirality has a ... living organisms. The inception of chirality from the elementary ... mysteries of the origin of life. Scientists at ...
... granted to start the first safety and tolerability trial ... an incurable, paralyzing neurodegenerative disorder that strikes 5 persons ... in the most active period of their lives − ... previously shown the possibilities for the use of VEGF ...
Cached Biology News:Argonne scientists discover possible mechanism for creating 'handedness' in biological molecules 2First trial in patients with a potential treatment of the incurable ALS muscle disease 2First trial in patients with a potential treatment of the incurable ALS muscle disease 3
Dual Color Mouse anti-Human Anti-Kappa FITC/CD19 PE Class: Antibody Product Group: Immunogluobulin...
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 50 ug...
Mouse monoclonal [M7-PB-E9] to pan alpha Sodium Potassium ATPase ( Abpromise for all tested applications)....
Transcription factor Sp2. [Source:Uniprot/SWISSPROT;Acc:Q02086] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Biology Products: